Optimizing the involvement of EFCCA patients in medicines-related decision making

Year: 2024

Publisher: Fundación Weber

Summary: Patient participation in drug decision-making is key to improving treatments. The European Federation of Crohn’s and Ulcerative Colitis Associations (EFCCA), in collaboration with the Weber Foundation, set up this pioneering initiative aimed at bridging the gap between the real needs of patients and the authorities’ expectations regarding their contributions, in order to optimize the participation of patient associations in the health technology assessment (HTA) process. Unlike traditional models, which primarily involve experts engaging patients for their insights, EFCCA has taken the lead in collaborating with experts to improve the assessment of healthcare technologies for IBD. The initiative highlights the need to include the patient perspective from the beginning of the process, providing training to enhance their input. It also stresses the importance of transparency and the credibility of patient associations. As the regulatory framework evolves, this transformation requires collaboration from all parties to create a more equitable healthcare system. Collaboration and knowledge will also be key to strengthening patient influence in HTA and ensuring decisions that are more responsive to their needs. This initiative has been financially supported by Pfizer.

How to cite: Zozaya N, Avendano L, Saldaña R. Optimizing the involvement of EFCCA patients in medicines-related decision making2024.  Madrid, España. Fundación Weber.